Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels

European Journal of Endocrinology

Volumn 165, Issue 1, 2011, Pages 63-68

  Koiou, Ekaterini ^a   Tziomalos, Konstantinos ^a   Katsikis, Ilias ^a   Kalaitzakis, Emmanuil ^a   Kandaraki, Eleni A ^a   Tsourdi, Elena A ^a   Delkos, Dimitrios ^a   Papadakis, Efstathios ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; ANDROGEN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; BLOOD; MEMBRANE MICROPARTICLE; PATHOLOGY; THROMBOCYTE; ANTHROPOMETRY; BODY WEIGHT; CIRCULATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; PHENOTYPE; TRANSVAGINAL ECHOGRAPHY;

ADULT; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE;

EID: 79959419961     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0144     Document Type: Article

References (31)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertility and Sterility 2004 81 19-25. (doi:10.1016/j.fertnstert.2003.10.004)
2. Ehrman DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236. (doi:10.1056/NEJMra041536)
3. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovary syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology and Metabolism 2006 91 781-785. (doi:10.1210/jc.2005-2153)
4. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovary syndrome: in defense of the Rotterdam criteria. Journal of Clinical Endocrinology and Metabolism 2006 91 786-789. (doi:10.1210/jc.2005-2501)
5. Zawadski JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, Current Issues in Endocrinology and Metabolism, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine, GE Merriam & SM Hershman, Boston: Blackwell, 1992.
6. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W & Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. (doi:10.1210/jc.2007-0425)
7. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH & Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Journal of Clinical Endocrinology and Metabolism 2008 93 470-476. (doi:10.1210/jc.2007-1756)
8. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J & Milic N. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. European Journal of Endocrinology 2006 155 131-136. (doi:10.1530/eje.1. 02187)
9. Legro RS, Kunselman AR, Dodson WC & Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 1999 84 165-169. (doi:10.1210/jc.84.1.165)
10. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G & Rini G. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. Journal of Clinical Endocrinology and Metabolism 2007 92 2500-2505. (doi:10.1210/jc.2006-2725)
11. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B & Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics and Gynecology 2005 106 131-137. (doi:10.1097/01.AOG.0000167408. 30893.6b)
12. Diamanti-Kandarakis E & Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clinical Endocrinology 2007 67 735-742. (doi:10.1111/j.1365-2265.2007.02954.x)
13. Moran L & Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Update 2009 15 477-488. (doi:10.1093/humupd/dmp008)
14. Morel O, Kessler L, Ohlmann P & Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 2010 212 367-376. (doi:10.1016/j.atherosclerosis.2010.03.019)
15. Mause SF & Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research 2010 107 1047-1057. (doi:10.1161/CIRCRESAHA.110.226456)
16. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R & Yamashita K. Correlation and association of plasma interleukin-6 and plasma platelet-derived microparticles, markers of activated platelets, in healthy individuals. Thrombosis Research 2010 125 e329-e334. (doi:10.1016/j.thromres. 2010.03.004)
17. Feng B, Chen Y, Luo Y, Chen M, Li X & Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2010 208 264-269. (doi:10.1016/j.atherosclerosis.2009.06.037)
18. Namba M, Tanaka A, Shimada K, Ozeki Y, Uehata S, Sakamoto T, Nishida Y, Nomura S & Yoshikawa J. Circulating platelet-derived microparticles are associatedwith atherothrombotic events: a marker for vulnerable blood. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 255-256. (doi:10.1161/01.ATV.0000252064.97632.2c)
19. Tan KT, Tayebjee MH, Lynd C, Blann AD & Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Annals of Medicine 2005 37 61-66. (doi:10.1080/07853890410018943)
20. Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, Araoz PA, Budoff MJ, Harman SM & Miller VM. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. American Journal of Physiology. Heart and Circulatory Physiology 2008 295 H931-H938. (doi:10.1152/ajpheart.00193.2008)
21. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S & Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. American Journal of Physiology. Endocrinology and Metabolism 2009 296 E238-E243. (doi:10.1152/ajpendo.90684.2008)
22. Morley JE, Patrick P & Perry HM. Evaluation of assays available to measure free testosterone. Metabolism 2002 5 554-559. (doi:10.1053/meta.2002. 31975)
23. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D & Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 12-19. (doi:10.1007/BF00280883)
24. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410. (doi:10.1210/jc.85.7.2402)
25. Murakami T, Horigome H, Tanaka K, Nakata Y, Ohkawara K, Katayama Y & Matsui A. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thrombosis Research 2007 119 45-53. (doi:10.1016/j.thromres.2005.12.013)
26. Helal O, Defoort C, Robert S, Marin C, Lesavre N, Lopez-Miranda J, Riserus U, Basu S, Lovegrove J, McMonagle J, Roche HM, Dignat-George F & Lairon D. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutrition, Metabolism, and Cardiovascular Diseases, 2011. In Press (doi:10.1016/j.numecd.2010.01.004)
27. Ueba T, Haze T, Sugiyama M, Higuchi M, Asayama H, Karitani Y, Nishikawa T, Yamashita K, Nagami S, Nakayama T, Kanatani K & Nomura S. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thrombosis and Haemostasis 2008 100 280-285. (doi:10.1160/TH07-11-0668)
28. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF & Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 4237-4245. (doi:10.1210/jc.2006-0178)
29. Carmina E & Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertility and Sterility 1999 71 319-322. (doi:10.1016/S0015-0282(98)00455-5)
30. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ & Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. British Journal of Obstetrics and Gynecology 2006 113 1210-1217. (doi:10.1111/j.1471-0528.2006.01008.x)
31. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G & Crowley WF. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. Journal of Clinical Endocrinology and Metabolism 2006 91 4842-4848. (doi:10.1210/jc.2006-1327)